Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Increases By 27.3%

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) saw a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 439,335 shares, an increase of 27.3% from the January 15th total of 345,021 shares. Based on an average trading volume of 174,125 shares, the days-to-cover ratio is presently 2.5 days. Approximately 1.1% of the company’s stock are sold short. Approximately 1.1% of the company’s stock are sold short. Based on an average trading volume of 174,125 shares, the days-to-cover ratio is presently 2.5 days.

MIRA Pharmaceuticals Stock Down 1.7%

Shares of MIRA Pharmaceuticals stock traded down $0.02 on Monday, reaching $1.16. The stock had a trading volume of 56,422 shares, compared to its average volume of 152,552. The stock has a market capitalization of $48.58 million, a P/E ratio of -0.76 and a beta of 1.80. The company has a 50 day moving average price of $1.41 and a 200 day moving average price of $1.43. MIRA Pharmaceuticals has a 1 year low of $0.73 and a 1 year high of $2.45.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its earnings results on Thursday, November 13th. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($1.07). On average, analysts forecast that MIRA Pharmaceuticals will post -0.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on MIRA shares. Rodman & Renshaw began coverage on shares of MIRA Pharmaceuticals in a report on Tuesday, January 13th. They issued a “buy” rating for the company. Wall Street Zen lowered shares of MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MIRA. XTX Topco Ltd acquired a new stake in MIRA Pharmaceuticals in the second quarter worth about $26,000. Creative Planning acquired a new stake in MIRA Pharmaceuticals in the 2nd quarter worth approximately $27,000. Fifth Third Bancorp acquired a new stake in MIRA Pharmaceuticals in the 4th quarter worth approximately $30,000. International Assets Investment Management LLC purchased a new stake in MIRA Pharmaceuticals during the 2nd quarter worth approximately $42,000. Finally, Two Sigma Investments LP increased its stake in MIRA Pharmaceuticals by 129.8% during the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after purchasing an additional 25,816 shares in the last quarter. 35.16% of the stock is owned by institutional investors and hedge funds.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.